WebJan 1, 2024 · for PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Breast Cancer The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for PHESGO effective January 1, 2024. TYPE CODE DESCRIPTION Diagnosis: ICD-10-CM C50.011–C50.019 C50.111–C50.119 C50.211–C50.219 C50.311–C50.319 … WebPHESGO should be administered every 3 weeks 1,2 Loading (initial) dose 1200 mg pertuzumab, 600 mg trastuzumab, 30,000 units hyaluronidase per 15 mL supplied in a …
Preparation & Storage PHESGO® (pertuzumab / trastuzumab ...
WebSee full prescribing information for details regarding concomitant use of simvastatin with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis. (2.5, 7.1) • Coumarin Anticoagulants: Obtain INR before simvastatin initiation and monitor INR during simvastatin dosage initiation or adjustment. • WebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body … shane hnidy eye injury
Phesgo Dosage & Drug Information MIMS Thailand
Webwhich can ensure validation of the testing procedures. For full instructions on assay performance and interpretation, please refer to the package leaflet of validated HER2 testing assays. For Phesgo dose recommendations in early and metastatic breast cancer please refer to Table 1. Table 1: Phesgo recommended dosing and administration WebDosage/Direction for Use. SC EBC & MBC Loading dose: Pertuzumab 1,200 mg/trastuzumab 600 mg for approx 8 min. Maintenance dose: Pertuzumab 600 mg/trastuzumab 600 mg for approx 5 min every 3 wk. Patient receiving taxane Administer prior to taxane. Recommended initial dose of docetaxel: 75 mg/m 2. EBC Neoadjuvant (pre-op): 3-6 cycles depending on ... shane hnidy stats